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We use surveillance data to describe influenza A and 
B virus circulation over two consecutive seasons with 
excess all-cause mortality in Europe, especially in peo-
ple aged 60 years and older. Influenza A(H3N2) virus 
dominated in 2016/17 and B/Yamagata in 2017/18. 
The latter season was prolonged with positivity rates 
above 50% among sentinel detections for at least 12 
weeks. With a current west–east geographical spread, 
high influenza activity might still be expected in east-
ern Europe.
The yearly influenza epidemics during each winter sea-
son vary in burden and severity. During the 2016/17 
and 2017/18 seasons, all-cause excess mortality was 
observed during periods of high influenza virus cir-
culation [1,2]. Our aim is to describe and compare the 
pattern of influenza virus circulation and related dis-
ease severity by number of patients and fatal cases 
in intensive care units (ICUs) across European Union/
European Economic Area (EU/EEA) countries for the 
seasons 2016/17 and 2017/18. As influenza circulation 
progressed from a west to east direction across Europe 
in 2017/18, a better understanding of the current epi-
demiological situation might help to prepare countries 
in the eastern part of the World Health Organization 
(WHO) European Region for high influenza activity and 
severity [3].
Influenza surveillance in Europe
The European Influenza Surveillance Network (EISN) 
performs influenza surveillance from week 40 to week 
20 of the following year [4,5]. Weekly epidemiologi-
cal and virological influenza data are collected from 
30 EU/EAA countries and 11 countries report data on 
severe and fatal cases with laboratory-confirmed influ-
enza in ICUs. Collected data in selected primary care 
settings include the percentage of these sentinel speci-
mens testing positive for influenza [6].
Influenza virus circulation in the 2016/17 
and 2017/18 seasons 
The influenza virus positivity rates among sentinel 
specimens in EU/EEA countries over the 2016/17 and 
2017/18 seasons are shown in Figure 1. 
2016/17 seasonal influenza epidemic
Sentinel surveillance outcome
The 2016/17 epidemic was characterised by an early 
start, with overall sentinel detections crossing the 10% 
positivity threshold in week 46/2016 (Figure 1) and 
with a dominance (75%; 10,242/13,584) of influenza 
A(H3N2) viruses among all positive sentinel specimens, 
17% (n = 2,318) influenza A unsubtyped, 1% (n = 172) 
A(H1N1)pdm09, 2% (n = 281) B no lineage, 1% (n = 117) 
B/Victoria and 3% (n  =  454) B/Yamagata lineage) [7]. 
Only Slovenia reported a substantial proportion (44%; 
113/259) of B/Yamagata viruses in sentinel specimens 
(Figure 2). The positivity rate in the EU/EEA remained 
above 10% for 27 consecutive weeks with a dominance 
of B/Yamagata viruses in the final weeks of the season. 
The peak phase with positivity levels above 50% (maxi-
mum positivity: 57%) lasted for 6 consecutive weeks.
Results from surveillance in intensive care 
units
During 2016/17, 10 countries (Czech Republic, 
Denmark, Finland, France, Ireland, Romania, Slovakia, 
Spain, Sweden, and the United Kingdom (UK)) reported 
a total of 3,959 patients admitted to ICUs with labora-
tory-confirmed influenza (Figure 3). Of these patients, 
96% (n  =  3,813) were infected with influenza A virus, 
with 92% (1,465/1,592) of the subtyped A viruses being 
2 www.eurosurveillance.org
Figure 1
Percentage positivity for influenza viruses among sentinel specimens, by week and season, European Union/European 
Economic Area, 2016/17 and 2017/18 (up to week 11)
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Figure 2
Distribution of viral types/subtypes in sentinel specimens by country, European Union/European Economic Area, influenza 
season 2016/17
Influenza viruses circulating
in 2016/17a
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EU/EEA: European Union/European Economic Area.
a Only sentinel specimens are included.
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Figure 3
Distribution of laboratory-confirmed influenza cases admitted to ICU, by age group and type/subtype, in the reporting 
European Union/European Economic Area countries, 2016/17 season (n = 2,827 patients)a
ICU: intensive care unit.
a Of the total reported 3,959 patients, 2,827 where age information was available are included in the figure.
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Figure 4
Distribution of viral types/subtypes in sentinel specimens by country, European Union/European Economic Area, influenza 
season 2017/18 (up to week 11)
EU/EEA: European Union/European Economic Area.
a Only sentinel specimens are included.
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A(H3N2). The majority of cases (81%; 3,194/3,959) 
were reported from three countries, namely France 
(n  =  1,469 cases), the UK (n  =  1,109) and Spain 
(n = 616). Most cases in the 2016/17 season occurred 
up to week 11, by which 97% (3,837/3,959) of all the 
season’s cases in ICU and 99% (593/599) of all fatal 
cases had been reported.
2017/18 seasonal influenza epidemic
Sentinel surveillance outcome
During the 2017/18 season, the influenza positivity of 
tested sentinel specimens passed the 10% threshold in 
week 47 2017, and the 50% threshold in week 52 2017. 
Positivity rates exceeded 52% for over 12 weeks indi-
cating an unusually protracted peak period of influ-
enza activity across the countries (maximum positivity: 
61%;  Figure 1). In the previous seven seasons, the 
number of weeks with a positivity of 50% and higher 
ranged between 0 (2009/10; 2013/14) and 8 (2012/13; 
2015/16) weeks.
During the initial weeks of the 2017/18 season, similar 
numbers of influenza A and B viruses were detected 
in sentinel specimens, but between weeks 48  2017 
and 11 2018, influenza B viruses were dominant (66%; 
12,455/18,888). Among B viruses with lineage deter-
mination, 97% (5,687/5,860) were of the Yamagata 
lineage. Overall during this period, 6% (n  =  1,102) 
unsubtyped influenza A, 17% (n  =  3,283) A(H1N1)
pdm09, 11% (n  =  2,048) A(H3N2), 35% (n  =  6,595) 
B without lineage determination, 1% (n  =  173) B/
Victoria and 30% (n = 5,687) B/Yamagata lineage were 
detected. All countries had a proportion of sentinel B 
viruses of 46% or higher. Both influenza A(H1N1)pdm09 
and A(H3N2) viruses co-circulated with B viruses, but 
the pattern and magnitude varied across countries. 
These different patterns are more visible at country-
level (Figure 4). 
Results from surveillance in intensive care 
units
Up to week 11  2018, 7,789 laboratory-confirmed influ-
enza cases in ICUs were reported from 10 countries 
(Czech Republic, Denmark, Finland, France, Ireland, the 
Netherlands, Romania, Spain, Sweden, and the UK). 
Altogether, the UK (n = 2,983), France (n = 2,614) and 
Spain (n  =  1,119) reported the vast majority of cases 
(86%; 6,716/7,789). Comparing data up to week 11 in 
2017/18 to the complete 2016/17 season, this is an 
increase of ICU cases by 169%, 78% and 82% in these 
countries, respectively (Figure 3, Figure 5).
Influenza A was detected in 52% (n  =  4,036) of the 
7,789 patients, and 59% (n  =  872) of the 1,471 sub-
typed influenza A viruses were reported as A(H1N1)
pdm09 with 51% (n = 449) of them reported by France.
The vast majority (81%; 190/234) of all B viruses as 
well as A(H3N2) viruses were detected in ICU patients 
aged 50 years and older. The majority (64%; 419/650) 
of patients infected with A(H1N1)pdm09 were 40 to 69 
years-old.
Disease severity in 2016/17 and 2017/18
The severity of disease caused by B viruses during the 
2017/18 season is also reflected in the high proportion 
of B infections among fatal outcomes reported from 
ICUs (49%; 420/851). This is in contrast with the previ-
ous season in which 1% (5/599) of fatal cases in ICUs 
died of influenza B infection. In 2016/17, 0.5% (3/599) 
of the fatal cases were infected with A(H1N1)pdm09, 
44% (266/599) with A(H3N2) and 54% (325/599) with 
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Figure 5
Distribution of laboratory-confirmed influenza cases admitted to ICU, by age group and type/subtype, in the reporting 
European Union/European Economic Area countries, 2017/18 season (up to week 11) (n = 4,754)a
a Of the total reported 7,789 patients, 4,754 where age information was available are included in the figure.
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an unsubtyped influenza A virus. In 2017/18, 15% 
(124/851) of the fatal cases were infected with A(H1N1)
pdm09, 5% (42/851) with A(H3N2) and 31% (265/851) 
with an unsubtyped influenza A virus.
Among all cases reported with influenza B infection in 
ICUs and known outcome, 5/52 (10%) died in 2016/17, 
while 420/1,983 (21%) died in 2017/18. More than 50% 
(333/636) of all fatal cases over 60 years of age had 
influenza B and among fatal cases infected with influ-
enza B virus, 79% (333/420) were 60 years of age and 
older. A similar distribution between virus type and 
age has been also observed in the B/Yamagata virus 
dominated season 2012/13.
Discussion
The ongoing 2017/18 influenza season with domi-
nant circulation of influenza B and a co-circulation of 
A(H1N1)pdm09 and/or A(H3N2) viruses is proving to 
have a severe impact, as did the 2016/17 season with 
its dominance of influenza A(H3N2). The dominance of 
A(H3N2) viruses associated with a high severity, pro-
longed season and all-cause excess mortality in the 
EU/EEA in 2016/17 [2] is comparable to the situation in 
the United States during the 2017/18 season [8]. The 
dominant B/Yamagata virus circulation with mixed A 
virus pattern in 2017/18 causing high severity, long 
duration of peak influenza activity and all-cause excess 
mortality in the EU/EEA is comparable to 2012/13, an 
influenza B/Yamagata virus dominated season with 
A(H1N1)pdm09 and A(H3N2) co-circulation [1,2,9,10]. 
Influenza A(H3N2) viruses are known to affect dispro-
portionately those aged above 65 years, leading to 
outbreaks in long-term care homes, increases in hos-
pitalisation and mortality in this age group [11,12]. B 
viruses are described as causing milder disease and 
affecting more the younger age groups [13]. In both 
seasons described here, however, we observed the 
highest number of severe cases in patients admitted 
to ICUs aged 60 years and older. As seen previously, 
patients infected with A(H1N1)pdm09 in ICU were 
slightly younger than patients infected with influenza 
A(H3N2) or B [14,15].
The reason for the prolonged and increased activity as 
well as the severe clinical impact of influenza B viruses 
during the 2017/18 season is not fully understood. 
Countries perform either sentinel or universal hospi-
tal surveillance and no major change in reporting has 
occurred which would explain the increase of cases in 
ICU [16].
Although the most commonly used trivalent vaccine 
contained the B/Victoria lineage in both 2016/17 and 
2017/18 seasons, a moderate vaccine effectiveness 
for B/Yamagata and A(H1N1)pdm09 in 2017/18 was 
observed; the effectiveness for A(H3N2) viruses in 
both seasons, however, was low [12,17]. The moderate 
and low vaccine effectiveness as well as low vaccine 
coverage might have contributed to the lower protec-
tion in the population together with an accumulation of 
susceptible people since the last dominant B/Yamagata 
circulation five seasons ago [18]. Further in-depth anal-
yses are needed to describe the mostly affected popu-
lation and identify relevant underlying co-morbidities 
and other factors, e.g. cold weather, that might have 
contributed to the prolonged virus activity and sever-
ity. Neuraminidase inhibitors remain an option for the 
prophylaxis and treatment of the currently circulating 
influenza viruses, and their use should be considered 
along the national and international guidance and rec-
ommendations, especially for cases with severe and 
rapidly progressing disease [19]. The season in Europe 
has progressed in a marked west–east direction and 
countries in the eastern part of the WHO European 
Region should be prepared for possible cases of severe 
disease and impact on healthcare services. However, 
influenza activity remains high also in central and 
western parts of Europe with continuously observed 
all-cause mortality.
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